We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
VERZENIO (Eli Lilly Australia Pty Ltd)
Product name
VERZENIO
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
141 working days (255)
Active ingredients
abemaciclib
Registration type
NCE/NBE
Indication
VERZENIO (tablets) is indicated for the treatment of hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or following prior endocrine therapy.
In pre- or peri-menopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.